Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gritstone Oncology (GRTS – Research Report) and Cano Health (CANO – Research Report).
Gritstone Oncology (GRTS)
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Gritstone Oncology, with a price target of $7.00. The company’s shares closed last Wednesday at $1.19, close to its 52-week low of $1.14.
According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gritstone Oncology with a $10.50 average price target, implying a 767.8% upside from current levels. In a report released today, B.Riley Financial also reiterated a Buy rating on the stock with a $8.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Cano Health (CANO)
Piper Sandler analyst Jessica Tassan reiterated a Sell rating on Cano Health today and set a price target of $0.50. The company’s shares closed last Wednesday at $0.27, close to its 52-week low of $0.22.
According to TipRanks.com, Tassan is a 1-star analyst with an average return of
Currently, the analyst consensus on Cano Health is a Moderate Sell with an average price target of $0.51.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GRTS:
- Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
- Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Gritstone bio to Participate in Upcoming Investor Conferences
- Gritstone bio, Genevant Sciences announce option, license agreement
- Gritstone bio and Genevant Sciences Announce Option and License Agreement
